OLMA

Olema Pharmaceuticals, Inc. [OLMA] Stock Forecast

Q: What is Olema Pharmaceuticals, Inc. stock symbol ?

Olema Pharmaceuticals, Inc. is a US stock, located in San francisco of Ca and trading under the symbol OLMA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

OLMA Stock Summary

OLMA has less than 1 year of cash runway

Top OLMA Correlated Resources

OLMA

Top 10 Correlated ETFs

OLMA

Top 10 Correlated Stocks

OLMA

In the News

04:05 22 Mar 2023 OLMA

Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference

SAN FRANCISCO, March 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 2:40 p.m. ET.

04:30 22 Mar 2023 OLMA

Olema Oncology to Participate at Upcoming Investor Conferences

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will present at the following upcoming investor conferences:

07:00 22 Mar 2023 OLMA

Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023, at 2:15 p.m. PT (5:15 p.m. ET).

04:30 22 Mar 2023 OLMA

Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference

SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Shane Kovacs, Chief Operating and Financial Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022, at 2:30 p.m. ET (11:30 a.m. PT).

04:30 22 Mar 2023 OLMA

Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference

SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 1:30 p.m. ET.

08:35 22 Mar 2023 OLMA

Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.

07:30 22 Mar 2023 OLMA

Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 14, 2022, at 11:30 a.m. ET (8:30 a.m. PT).

07:30 22 Mar 2023 OLMA

Olema Oncology to Present at Cowen 42nd Annual Health Care Conference

SAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 2:50 p.m. ET (11:50 a.m. PT).

07:30 22 Mar 2023 OLMA

Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m. ET (2:15 p.m. PT).

02:36 22 Mar 2023 OLMA

Olema Pharmaceuticals (OLMA) Stock: Why The Price Jumped Today

The stock price of Olema Pharmaceuticals Inc (NASDAQ: OLMA) increased by over 9% during intraday trading today. This is why it happened.

OLMA Financial details

Company Rating

Neutral

Market Cap

147.49M

Income

-104.79M

Revenue

Book val./share

4.94

Cash/share

5.11

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

08 May 2023

P/E

-0.97

Forward P/E

PEG

-0.21

P/S

P/B

0.67

P/C

0.71

P/FCF

-1.91

Quick Ratio

17.77

Current Ratio

17.93

Debt / Equity

0.09

LT Debt / Equity

0.01

EPS (TTM)

-2.62

EPS next Y

EPS next Q

EPS this Y

45.96%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

14.04%

SMA20

-15.78%

SMA50

43.02%

SMA100

16.62%

Inst Own

83.08%

Inst Trans

-0.43%

ROA

-65%

ROE

-60%

ROC

-0.46%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

42.07M

Shs Float

23.95M

Target Price

52W Range

2.0-6.08

52W High

-39.33%

52W Low

+82%

RSI

39.71

Rel Volume

0.74

Avg Volume

149.01K

Volume

110.85K

Perf Week

-6.43%

Perf Month

-19.65%

Perf Quarter

28.17%

Perf Half Y

6.43%

Beta

2.36087

Volatility

0.15%, 0.36%

Prev Close

0.83%

Price

3.64

Change

0.28%

OLMA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-0.16	-0.6	-3.15	-1.8	-2.62
Operating cash flow per share	-0.15	-0.43	-2.83	-1.28	-2.05
Free cash flow per share	-0.15	-0.43	-2.84	-1.28	-2.05
Cash per share	0.22	0.01	48.22	7.25	5.11
Book value per share	-0.45	-1.47	48.16	7.18	4.94
Tangible book value per share	-0.45	-1.47	-0.6	7.18	4.94
Share holders equity per share	-0.45	-1.47	48.16	7.18	4.94
Interest debt per share	0	0	0.09	0.13	0.06
Market cap	690.83M	353.86M	337.59M	370.73M	97.99M
Enterprise value	687.68M	353.79M	-956.82K	362.07M	76.85M
P/E ratio	-314.44	-81.99	-15.26	-5.21	-0.94
Price to sales ratio	0	0	0	0	0
POCF ratio	-317.48	-114.85	-16.99	-7.31	-1.19
PFCF ratio	-317.48	-114.85	-16.95	-7.31	-1.19
P/B Ratio	-110.04	-33.4	1	1.3	0.5
PTB ratio	-110.04	-33.4	1	1.3	0.5
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-318.22	-82.14	0.04	-5.1	-0.73
EV to operating cash flow	-316.03	-114.83	0.05	-7.14	-0.94
EV to free cash flow	-316.03	-114.83	0.05	-7.14	-0.94
Earnings yield	0	-0.01	-0.07	-0.19	-1.07
Free cash flow yield	0	-0.01	-0.06	-0.14	-0.84
Debt to equity	-1.52	-1.01	0.01	0.04	0.09
Debt to assets	2.92	81.26	13.4	0.04	0.08
Net debt to EBITDA	1.46	0.02	15.78	0.12	0.2
Current ratio	16.13	0.07	0.07	32.23	12.62
Interest coverage	-74.25	0	-32.97	0	0
Income quality	0.99	0.71	0.9	0.71	0.78
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	-5.09	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	1.25	4.44	58.43	17.03	17.06
ROIC	0.66	4.6	0.03	-0.27	-0.64
Return on tangible assets	-0.67	-32.7	-64.64	-0.24	-0.49
Graham Net	-0.45	-1.48	47.56	6.97	4.66
Working capital	3.04M	-1.28M	-4.24M	281.67M	192.35M
Tangible asset value	-6.28M	-10.59M	-4.24M	284.57M	197.55M
Net current asset value	-6.31M	-10.62M	-4.24M	279.31M	190.8M
Invested capital	0	0	0	0.02	0.01
Average receivables	0	0	0	0	0
Average payables	0	525.5K	827K	371K	198.5K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0.35	0.41	-0.07	-0.25	-0.53
Capex per share	0	0	-0.01	0	0

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-1.79	-0.58	-0.82	-0.57	-0.65
Operating cash flow per share	-0.47	-0.45	-0.66	-0.45	-0.49
Free cash flow per share	-0.45	-0.45	-0.66	-0.45	-0.49
Cash per share	7.23	6.72	6.03	5.56	5.11
Book value per share	7.16	6.65	5.92	5.44	4.94
Tangible book value per share	7.16	6.65	5.92	5.44	4.94
Share holders equity per share	7.16	6.65	5.92	5.44	4.94
Interest debt per share	0.13	0.08	0.09	0.09	0.06
Market cap	371.99M	169.7M	162.47M	110.5M	97.99M
Enterprise value	363.33M	151.23M	141.03M	86.53M	76.85M
P/E ratio	-1.31	-1.84	-1.24	-1.22	-0.94
Price to sales ratio	0	0	0	0	0
POCF ratio	-20	-9.48	-6.14	-6.14	-4.97
PFCF ratio	-20.98	-9.46	-6.14	-6.09	-5.02
P/B Ratio	1.31	0.64	0.69	0.51	0.5
PTB ratio	1.31	0.64	0.69	0.51	0.5
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-5.12	-6.65	-4.36	-3.93	-2.86
EV to operating cash flow	-19.53	-8.45	-5.33	-4.81	-3.9
EV to free cash flow	-20.5	-8.43	-5.33	-4.77	-3.94
Earnings yield	-0.19	-0.14	-0.2	-0.21	-0.27
Free cash flow yield	-0.05	-0.11	-0.16	-0.16	-0.2
Debt to equity	0.04	0.05	0.06	0.07	0.09
Debt to assets	0.04	0.04	0.06	0.06	0.08
Net debt to EBITDA	0.12	0.81	0.66	1.09	0.79
Current ratio	32.23	26.57	19.75	17.93	12.62
Interest coverage	0	-106.67	-80.22	-37.33	0
Income quality	0.26	0.78	0.81	0.79	0.75
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0.01	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	-0.36	-0.25	-1.53	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	16.98	9.3	10.47	8.33	8.53
ROIC	-0.08	-0.1	-0.17	-0.13	-0.16
Return on tangible assets	-0.24	-0.08	-0.13	-0.1	-0.12
Graham Net	6.94	6.41	5.67	5.21	4.66
Working capital	281.67M	260.05M	230.72M	212.51M	192.35M
Tangible asset value	284.57M	265.09M	236.28M	217.7M	197.55M
Net current asset value	279.31M	257.89M	228.71M	210.76M	190.8M
Invested capital	0.02	0.01	0.01	0.01	0.01
Average receivables	0	0	0	228.5K	228.5K
Average payables	164.5K	145.5K	194K	67K	194K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.25	-0.09	-0.14	-0.1	-0.13
Capex per share	0	0	0	0	0

OLMA Frequently Asked Questions

What is Olema Pharmaceuticals, Inc. stock symbol ?

Olema Pharmaceuticals, Inc. is a US stock , located in San francisco of Ca and trading under the symbol OLMA

What is Olema Pharmaceuticals, Inc. stock quote today ?

Olema Pharmaceuticals, Inc. stock price is $3.64 today.

Is Olema Pharmaceuticals, Inc. stock public?

Yes, Olema Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 149.01K
Market Capitalization 147.49M
Employee 73
CEO Dr. Sean P. Bohen M.D., Ph.D.
Headquarters San Francisco,CA,US
IPO Date 2020-11-19
Website https://www.olema.com

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.